The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Jazz Pharmaceuticals plc (JAZZ) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $156.54. The Jazz Pharmaceuticals plc has recorded 102,017 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $156.54 and fluctuated between $157.43 as its day high and $155.71 as its day low. The current market capitalization of Jazz Pharmaceuticals plc is $9.98B. A total of 0.8 million shares were traded on the day, compared to an average of 534.85K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, JAZZ has seen 5 BUY and 15 SELL insider trades, representing the acquisition of 74,199 and the disposition of 60,252 shares. Over the last 12 months, there were 43 BUYs and 103 SELLs from insiders. Insiders purchased 340,580 shares during that period but sold 234,187.
In the most recent transaction, ENRIGHT PATRICK G sold 2,000 shares of JAZZ for 152.88 per share on Nov 22. After the transaction, the Director now owns 0 company shares. In a previous transaction on Nov 22, ENRIGHT PATRICK G sold 4,974 shares at 149.48 per share. JAZZ shares that Director owns now total 19,112.
Among the insiders who sold shares, Patil Neena M disposed of 3,510 shares on Nov 16 at a per-share price of $142.34. This resulted in the EVP & Chief Legal Officer holding 26,769 shares of JAZZ after the transaction. In another insider transaction, Larkin Finbar sold 197 shares at $149.33 per share on Nov 14. Company shares held by the SVP, Technical Operations now total 19,409.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for JAZZ in the last 3 months, the mean price target is $201.82 with high estimates of $240.00 and low estimates of $180.00. In terms of 52-week highs and lows, JAZZ has a high of $169.98 and a low of $119.64.
As of this writing, JAZZ has an earnings estimate of $4.66 per share for the current quarter. EPS was calculated based on a consensus of 16 estimates, with a high estimate of $4.98 per share and a lower estimate of $4.11. The company reported an EPS of $3.73 in the last quarter, which was -2.90% lower than expectations of $3.84.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 18 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for JAZZ is Underweight with a score of 4.63. A total of 14 analysts rated the stock as Buy while 2 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.